Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – INmune Bio, Inc.’s (NASDAQ: INMB) Lead Compound XPro1595 Data to be Presented at the Society for Neuroscience’s Annual Meeting

INmune Bio, Inc. (NASDAQ: INMB) today announced a poster presentation related to its program in Alzheimer’s disease at the upcoming Society for Neuroscience (“SfN”) 49th Annual Meeting to be held at McCormick Place in Chicago from Oct. 19–23, 2019. The company also announced that its poster was selected for presentation during the meeting’s press conference. The data from studies involving the use of INmune Bio’s XPro1595, as presented in a poster by Malú Tansey, Ph.D., Professor of Neuroscience and Director of the Center for Translational Research in Neurodegenerative Disease at the University of Florida College of Medicine, demonstrate the critical role of the immune system on an individual’s genetic risk in the context of environmental exposures, such as a diet high in fat and sugar, for neurodegenerative diseases such as Alzheimer’s. “It’s become clear that neurological disorders can arise from or be exacerbated by innate immune dysfunction and chronic inflammation resulting from both genetic and environmental factors such as diet,” Dr. Tansey said in the news release. “Harnessing the power of the immune system could potentially delay or perhaps even prevent some of these neurological disorders. Our results provide a compelling rationale for moving forward with a clinical trial in early Alzheimer’s disease patients.”

To view the full press release, visit

About INmune Bio, Inc.

INmune Bio, Inc. is a publicly traded, clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer (“NK”) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid-derived suppressor cells (“MDSC”), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published:

This entry was posted in INmune Bio Inc. INMB, MissionIRNewsBreaks. Bookmark the permalink.

Comments are closed.